IMUNON, Inc. announced on July 30, 2025, that the first patient has been dosed in its pivotal Phase 3 OVATION 3 Study. This study evaluates the company’s lead candidate, IMNN-001, for the treatment of women with newly diagnosed advanced ovarian cancer.
The first patient was dosed by Melanie K. Bergman, M.D., FACOG, a Gynecologic Oncologist with Providence Medical Group. IMUNON is actively initiating additional trial sites and accelerating patient enrollment activities, with multiple patients currently in screening.
IMNN-001 has demonstrated significant therapeutic potential and consistent overall survival benefit in previous clinical trials. Dosing the first patient in this Phase 3 study is a crucial step towards potentially bringing a transformative therapy to women who currently have limited effective options beyond chemotherapy and surgery.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.